Lilly's Foundayo lowers heart attack, stroke risk in study [USA TODAY]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: USA TODAY
The U.S. Food and Drug Administration approved the pill, Foundayo, for weight loss earlier this month, intensifying Lilly's competition with Danish rival Novo Nordisk NOVOb.CO, whose oral Wegovy ?has been on the market since January. The late-stage study data also adds to the obesity drug's potential in diabetes, boosting Lilly's position in the multi-billion-dollar market, where drugmakers are racing to develop more convenient oral options as an alternative to injectables. Lilly said it will seek U.S. approval of Foundayo for type 2 diabetes under the Commissioner's National Priority Review Voucher, which aims to speed up FDA decisions on drugs deemed critical to public health or national security. The company will submit an application by the end of the second quarter, it added. The trial of 2,700 patients, who were at increased cardiovascular risk, showed Foundayo lowered the risk of heart attack, stroke or cardiovascular death by 16%, when compared with those on insulin g
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Nurix Therapeutics, Inc. (NRIX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- Adagene Looks Attractive With ADG126 And Validating Partnerships [Seeking Alpha]Seeking Alpha
- Juvisé Pharmaceuticals Formally Approved the Appointments of Frédéric Mascha as Executive Chairman and Chairman of the Supervisory Committee and the Nomination of Renaud Sermondade as the Group's New CEO [Yahoo! Finance]Yahoo! Finance
- New Research Highlights Cas-CLOVER Gene Editing Potential for CHO Cell Line DevelopmentPR Web
- Navan Selected by Opella to Streamline Global Travel and Expense [Yahoo! Finance]Yahoo! Finance
SNY
Sec Filings
- 4/15/26 - Form 6-K
- 4/10/26 - Form SCHEDULE
- 3/31/26 - Form 6-K
- SNY's page on the SEC website